| Literature DB >> 32989469 |
Karin Ringqvist1, Kristian Borg, Marika C Möller.
Abstract
OBJECTIVE: To determine whether the psychological benefits of intense, inpatient, multimodal rehabilitation for persons with Huntingtons disease (HD), as found in earlier studies, also apply in a shorter, day-care setting.Entities:
Keywords: Huntington�s disease; anxiety; depression; health-related quality of life; multimodal treatment; sense of coherence
Mesh:
Year: 2021 PMID: 32989469 PMCID: PMC8772368 DOI: 10.2340/16501977-2748
Source DB: PubMed Journal: J Rehabil Med ISSN: 1650-1977 Impact factor: 2.912
Self-reported evaluation at the end of the rehabilitation programme (n = 20)
| Questions | Mean (SD) | Median (range) |
|---|---|---|
| What is your overall impression of the rehabilitation you have received? | 4.6 (0.6) | 5.0 (3–5) |
| How do you feel that you have been treated by the staff? | 4.8 (0.4) | 5.0 (4–5) |
| Has the content of the rehabilitation been relevant to you? | 4.3 (0.8) | 4.0 (2–5) |
| Has the rehabilitation given you increased knowledge about your difficulties and resources? | 4.2 (0.8) | 4.0 (2–5) |
| Do you feel that rehabilitation has affected your everyday life in any way? | 4.5 (0.6) | 4.5 (4–5) |
| Total score | 22.4 (2.7) | 23.0 (15–25) |
For each question, the minimum value was 1 (not good/not at all/worsened the situation) and the maximum value was 5 (very good/completely/improved the situation). Minimum value on the total score was 5, maximum 25. SD; standard deviation.
Psychological outcome measures as measured at baseline (T1) and the end of the rehabilitation programme (T2), mean/median difference and statistical results (n = 20)
| Variables | T1 | T2 | Diff T2–T1 | Effect size | |
|---|---|---|---|---|---|
| HADS-A ( | 8.3 (5.1) | 6.4 (4.4) | –1.9 |
| 0.4 |
| HADS-A, median (range) | 9.0 (0–16) | 6.5 (0–21) | –2.5 | 0.13 | 0.3 |
| HADS-D ( | 4.9 (3.5) | 4.1 (3.1) | –0.8 |
| 0.3 |
| HADS-D, median (range) | 4.5 (0–14) | 4.0 (0–16) | –0.5 | 0.13 | 0.1 |
| EQ-VAS, mean (SD) | 67.3 (20.7) | 77.3 (17.1) | 9.9 |
| 0.5 |
| SOC-29 CP, median (range) | 41.0 (27–58) | 42.5 (27–56) | 1.5 | 0.85 | |
| SOC-29 MA, median (range) | 46.5 (21–65) | 44.5 (27–63) | –2.0 | 0.99 | |
| SOC-29 ME, median (range) | 41.0 (21–52) | 36.5 (27–54) | –4.5 | 0.48 |
Effect size (Cohen’s d) was calculated when the p-value was < 0.2. Effect sizes < 0.2 are considered trivial, 0.2 represents a small effect size, 0.5 a medium effect size, and 0.8 a large effect size (34). p-value ≤ 0.05 in bold. HADS-A: Hospital Anxiety and Depression Scale, Anxiety; HADS-D: Hospital Anxiety and Depression Scale, Depression; EQ-VAS: EuroQol Visual Analogue Scale; SOC-29 CP: Sense of Coherence – 29 item scale, Comprehensibility; SOC-29 MA: Sense of Coherence – 29 item scale, Manageability; SOC-29 ME: Sense of Coherence – 29 item scale, Meaningfulness; Diff: difference; SD: standard deviation.
Outlier excluded.
Fig. 1Percentage of patients (n = 20) who had Hospital Anxiety and Depression Scale (HADS) subscale scores indicating a possible anxiety/depression state with clinical significance (≥ 8) (24) at baseline (T1) and the end of the rehabilitation programme (T2).
Physical outcome measures as measured at baseline (T1) and the end of the rehabilitation programme (T2), mean/median difference and statistical results
| Variables | T1 | T2 | Diff T2–T1 | Effect size | |
|---|---|---|---|---|---|
| Mini-BEST ( | 22.0 (9–26) | 24.0 (15–27) | 2.0 |
| 0.7 |
| TUG ( | 10.2 (5.2) | 9.2 (3.3) | –1.0 | 0.11 | 0.2 |
| 6MWT ( | 488.2 (109.7) | 506.2 (112.8) | 18.0 | 0.12 | 0.2 |
Effect size (Cohen’s d) was calculated when the p-value was <0.2. Effect sizes <0.2 are considered trivial, 0.2 represents a small effect size, 0.5 a medium effect size and 0.8 a large effect size (34). A reduced number of patients is due to missing data. p-value ≤ 0.05 in bold.
Mini-BEST: Mini-Balance Evaluation Systems Test; TUG: Timed Up and Go test; 6MWT: 6-Minute Walk Test; Diff: difference; SD: standard deviation.